癌症治疗：硼中子俘获治疗/ BNCT治疗开始：由京都大学/住友重工业开发
癌症治疗：
福岛/脑神经研究所（东北集团）：
硼中子俘获疗法（BNCT）作为“下一代放射癌治疗方法”引起了人们的关注。
这是世界上第一家由南东北BNCT研究中心（主任高井义广）创办的私立医院。
BNCT设备：
由京都大学和住友重工业共同开发。
从2018年到2019年，我们进行了“颈部和颈部以上颈部癌症的临床研究”。
总共进行了21项头颈癌临床试验。
临床试验结果：
第90天的局部效果
在5例“完全反应”中，癌症消失了，
有10例“部分反应”下降了30％或更多，
表示癌症缩小或消失的患者比例的“反应率”为71.4％。
两年生存率为85％：
患者发生的大多数不良事件都是轻度的。
高井理事长解释说“有效而安全的治疗”。
福岛/郡山（产经新闻）
https://news.yahoo.co.jp/articles/4f9b9719bd630faae9cc94a1d4d2aa968a12a27e
The world’s first male patient with pharyngeal cancer was treated with the accelerator-based BNCT (Boron Neutron Capture Therapy)
on May 26, 2020 at Southern TOHOKU BNCT Research Center, Southern TOHOKU Hospital Group.
At 11 a.m., the Founder and Chairman of the Board Dr. Kazuo Watanabe was invited to press the button to switch on the BNCT device.
The radiotherapy
was given by Prof. Yoshihiro Takai, Director of BNCT Research Center and Dr. Katsumi Hirose, Vice Director of BNCT Research Center.
The male patient in his 50s
was successfully treated. He is our center’s first clinical case since the AB-BNCT system and boron drug obtained an approval from Japanese government in March 2020.
BNCT treatment
will be covered by national health insurance in Japan from June 2020.
BNCT, which is one of particle beam therapies, causes reactions between low-energy thermal neutrons and tumor-seeking boron compounds to destroy cancer cells with pinpoint accuracy.
In addition, BNCT is a body-friendly treatment that can minimize negative effects to normal cells and the burdens to patients.
Locally unresectable recurrent or unresectable advanced head and neck cancer with radiation resistant is expected to become indications.
Clinical trials will aim to expand other indications in the near future. For full details visit
http://southerntohoku-bnct.com/
Southern TOHOKU Hospital Group
http://www.sthg-jp.com/motion.asp?newsid=9220&menuid=10523&lgid=1&siteid=100511